

ASSESSING BIODISTRIBUTION OF BIOMEDICAL CELLULAR PRODUCT BASED ON HUMAN CHONDROCYTES FOLLOWING IMPLANTATION TO BALB/C NUDE MICE

Pikina AS¹✉, Golubinskaya PA¹, Ruchko ES², Kozhenevskaya EV³, Pospelov AD³, Babayev AA³, Ereemeev AV^{1,2}

¹ Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia

² Koltzov Institute of Developmental Biology of Russian Academy of Sciences, Moscow, Russia

³ Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia

Despite the prospects of the approach to cell therapy of cartilage damage in humans involving autologous chondrocytes, similar technologies are just beginning to be introduced into medical practice in the Russian Federation. In this regard, the development of biomedical cell products (BCPs) for cartilage tissue repair is quite topical, while the use of organoid technology is the most close to the native tissue conditions. According to requirements of legislation of the Russian Federation, it is necessary to assess biodistribution characterizing migration potential of the cells, their tropism for body tissues following implantation within the framework of preclinical trials. The study was aimed to assess biodistribution of novel BCP based on human chondrocytes in the form of chondrospheres after subcutaneous implantation in Balb/c nude mice. Implantation to 12 mice was performed during the first phase, along with administration of saline to 12 control animals. Weighting and follow-up were conducted for 90 days. Then mice were withdrawn from the experiment to collect samples of organs and tissues for histological analysis of the implant, estimation of its viability, integration. During the second phase biodistribution was assessed by PCR in order to detect human DNA in the organ and tissue samples. Chondrospheres successfully integrated in the tissues surrounding the inoculation zones and formed cartilage tissue. No significant ($p < 0.05$) changes in weight were reported. No human DNA found in chondrosphere implantation zones was detected in the samples collected from other organs and tissues. BCP demonstrated no biodistribution across other tissues and organs of mice 90 days after implantation, which suggested that the product developed was safe.

Keywords: biomedical cellular product, chondrocytes, biodistribution, preclinical trials, chondrospheres

Funding: the study was performed under the State Assignment "Chondrosphere", R&D project ID AAAA-A19-119052890054-4.

Acknowledgments: the authors express their gratitude to the research staff of the laboratory of cell biology, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of FMBA of Russia, for methodological support provided during the study.

Author contribution: Pikina AS — literature review, literature source collection and analysis, manuscript writing; Golubinskaya PA — data acquisition and analysis, manuscript editing; Ruchko ES — data acquisition and analysis; Kozhenevskaya EV — carrying out work at the vivarium; Pospelov AD — histological analysis; Babayev AA — animal experiment management; Ereemeev AV — experimental design, final correction of the manuscript. All authors confirm compliance of authorship to ICMJE international criteria.

Compliance with the ethical standards: the study was approved by the Bioethics Commission of the Lobachevsky State University of Nizhny Novgorod (protocol № 73 dated 17 April 2023).

✉ **Correspondence should be addressed:** Arina S. Pikina
Malaya Pirogovskaya, 1a, Moscow, 119435, Russia; arina.pikina@yandex.ru

Received: 05.11.2023 **Accepted:** 17.12.2023 **Published online:** 31.12.2023

DOI: 10.47183/mes.2023.057

ИССЛЕДОВАНИЕ БИОРАСПРЕДЕЛЕНИЯ БИМЕДИЦИНСКОГО КЛЕТОЧНОГО ПРОДУКТА НА ОСНОВЕ ХОНДРОЦИТОВ ЧЕЛОВЕКА ПРИ ИМПЛАНТАЦИИ МЫШАМ ЛИНИИ BALB/C NUDE

А. С. Пикина¹✉, П. А. Голубинская¹, Е. С. Ручко², Е. В. Коженевская³, А. Д. Поспелов³, А. А. Бабаев³, А. В. Еремеев^{1,2}

¹ Федеральный научно-клинический центр физико-химической медицины имени Ю. М. Лопухина, Москва, Россия

² Институт биологии развития имени Н. К. Кольцова Российской Академии Наук, Москва, Россия

³ Нижегородский государственный университет имени Н. И. Лобачевского, Нижний Новгород, Россия

Несмотря на перспективность подхода клеточной терапии повреждений хряща человека с помощью аутологичных хондроцитов, подобные технологии только начинают внедрять в медицинскую практику в Российской Федерации. В связи с этим разработка биомедицинских клеточных продуктов (БМКП) для восстановления хрящевой ткани достаточно актуальна, а использование органоидных технологий наиболее приближено к условиям нативной ткани. Согласно требованиям законодательства РФ, в рамках доклинических исследований необходимо изучение биораспределения, характеризующего миграционный потенциал клеток, их тропность к тканям организма при имплантации. Целью работы было исследовать биораспределение нового БМКП на основе хондроцитов человека в виде хондросфер после подкожной имплантации мышам линии Balb/c nude. На первом этапе осуществляли имплантацию 12 мышам, а также введение физиологического раствора 12 контрольным животным. В течение 90 дней проводили взвешивание и наблюдение, а затем выводили мышей из эксперимента для получения образцов органов и тканей для гистологического анализа импланта, оценки его состоятельности, интеграции. На втором этапе изучали биораспределение методом ПЦР для выявления ДНК человека в образцах тканей и органов. Хондросферы успешно интегрировались в окружающие ткани зоны инокуляции, формировали хрящевую ткань. Статистически значимых ($p < 0,05$) изменений в весе не зафиксировали. В образцах из зоны имплантации хондросфер была выявлена ДНК человека, которую не обнаруживали в других органах и тканях. БМКП через 90 дней после имплантации демонстрировал отсутствие биораспределения в другие ткани и органы мышей, что свидетельствует о безопасности разрабатываемого продукта.

Ключевые слова: биомедицинский клеточный продукт, хондроциты, биораспределение, доклинические исследования, хондросферы

Финансирование: научное исследование проведено в рамках государственного задания «Хондросфера», номер государственного учета НИОКТР AAAA-A19-119052890054-4.

Благодарности: авторы выражают свою признательность научным сотрудникам лаборатории клеточной биологии ФГБУ ФНКЦ ФХМ ФМБА за методологическую поддержку в процессе исследования.

Вклад авторов: А. С. Пикина — обзор литературы, сбор и анализ литературных источников, написание текста статьи; П. А. Голубинская — получение и анализ данных, редактирование текста статьи; Е. С. Ручко — получение и анализ данных; Е. В. Коженевская — проведение работ в виварии; А. Д. Поспелов — гистологический анализ; А. А. Бабаев — курация экспериментальной части на животных; А. В. Еремеев — дизайн эксперимента, финальная корректировка текста статьи. Все авторы подтверждают соответствие своего авторства международным критериям ICMJE.

Соблюдение этических стандартов: исследование было одобрено Комиссией по биоэтике Нижегородского государственного университета имени Н. И. Лобачевского (протокол № 73 от 17 апреля 2023 г.).

✉ **Для корреспонденции:** Арина Сергеевна Пикина
ул. Малая Пироговская, д. 1а, г. Москва, 119435, Россия; arina.pikina@yandex.ru

Статья получена: 05.11.2023 **Статья принята к печати:** 17.12.2023 **Опубликована онлайн:** 31.12.2023

DOI: 10.47183/mes.2023.057

Advances of recent years in the development of various approaches to cell therapy for cartilage tissue damage enable treatment of some joint disorders, including disorders associated with human cartilage lesions of multifactorial etiology [1]. Implantation of autologous chondrocytes is considered to be an effective and promising method to treat cartilage tissue damage with minimal risk of adverse events [2]. The principle of this procedure consists in scaling up and culturing chondrocytes obtained from the biopsy specimen of the patient's articular cartilage fragment with subsequent transplantation of cells immediately into the defect [2]. The researchers became more and more interested in cell therapy since the first report of implantation of autologous chondrocytes into the damaged area of human articular cartilage [3]; new methods to modify and optimize this approach appeared over the decade [1]. The use of biomedical cell products (BCPs) based on autologous chondrocytes was superior to more conventional methods, arthroscopic debridement and microdamage, in terms of efficacy [4–7]. Today, a number of BCPs are through various phases of pre-clinical and clinical trials [1, 2, 6, 8, 9]; some products are approved for treatment of the human cartilage focal lesions [11–14].

Spheroids, the 3D structures resulting from self-aggregation of cells cultured under certain conditions, have many advantages over BCPs of other types when used for treatment of articular cartilage defects [15]. Thus, 3D conditions have a beneficial effect on proliferative activity and phenotypic stability of mature chondrocytes [9]. In contrast to suspension of autologous chondrocytes, which become capable of producing extracellular matrix (ECM) only after a certain time after transplantation, the cells comprised in spheroids can secrete the ECM components even in the phase of culturing [16, 17]. In addition, autologous spheroids do not require using third-party biomaterials, they easily integrate into the tissue in the damaged area; there is no need for systemic immunosuppression after implantation [15]. In combination, specified properties of spheroid BCPs can contribute to high-quality filling of the cartilage tissue defect. This, the efficacy of spheroids based on autologous chondrocytes has been demonstrated in animal models [17] and clinical trials [18, 19]. Spheroid BCPs have shown significantly better therapeutic effect in terms of structural cartilage defect restoration compared to the microdamage procedure [6, 7].

SpherоХТМ (Co.don; Germany), one of the globally approved cell therapy drugs for restoration of human articular cartilage defects, represents a spheroid BCP. Today, the Generium company produces this drug under license from Co.don and completes phase III clinical trial in the Russian Federation [10]. At the same time, no analogues of such BCPs are available in the Russian Federation. Thus, the only product that is, in fact, a technology transfer from Co.don, is currently undergoing clinical trials in the Russian Federation. Given optimistic results of the cell therapy trials conducted by foreign partners, the development and introduction of such technology into research and clinical practice in the Russian Federation seems to be very topical.

The main task of working with BCPs is to maintain efficacy and meet the critical quality parameters to ensure safety and the expected effect, which should be predicted before the start of the clinical trial. That is why BCPs, as all other medications, must meet strict requirements to be approved by the authorities for further research and implementation [8]. This requires the development and implementation of appropriate assessment methods to evaluate the cell-based product before and after implantation within the framework of pre-clinical trial [19, 20]. Thus, it is necessary to identify the major risk factors, such as

tumorigenicity, carcinogenicity and biodistribution, before the beginning of pre-clinical trial involving animals [21].

Biodistribution is one of the most important safety criteria characterizing migration potential of the cells comprised in BCP after implantation, along with the capabilities of forming ectopic tissue and persisting inside/outside the administration site [9, 22–24]. Biodistribution is usually assessed in immunodeficient animal models; subcutaneous implantation is preferred due to its less invasive nature [24]. Since the tested product should be as close as possible or similar to the final BCP variant based on its properties, it is advisable to avoid the use of fluorescent tags or any other approaches potentially changing the product structure and properties when assessing biodistribution [8].

The study was aimed to assess biodistribution of the Chondrosphere spheroid BCPs designed for treatment of articular cartilage lesions in humans after subcutaneous implantation to the Balb/c Nude immunodeficient mice.

METHODS

Legal regulation

The study represents a preclinical trial of novel BCP conducted in accordance with the current regulatory requirements [21, 25–27]. The study was carried out according to the approved written plan and Standard Operating Procedures. The employees, who took part in the experiment, were trained to ensure proper, humane care and use of laboratory animals.

Spheroid BCPs

The studied BCPs represented a 3D culture of spheroids based on human chondrocytes obtained using the Aggre Well 800 microwell plate (STEMCELL Technologies; Canada) in accordance with the manufacturer's protocol. The number of cells per microwell of the plate was $4\text{--}5 \times 10^3$. The spheroids obtained (the cellular or tissue-engineered product is referred to as Chondrosphere) were cultured in miniature bioreactors on the 3D orbital shaker (Infors HT; Switzerland) at 37 °C and 5% CO₂ [28]. Advanced DMEM (Gibco, Thermo Fisher Scientific; USA) supplemented with 10% fetal bovine serum (FBS), 50 µM β-mercaptoethanol, 10 ng/ml bFGF (STEMCELL Technologies; Canada), 100X Glutamax (Gibco, Thermo Fisher Scientific; USA), 50X B27 (GIBCO, Thermo Fisher Scientific), 1% Insulin-Transferrin-Selenium (ITS) (PANECO; Russia), 50 µg/ml of ascorbic acid (Sigma Aldrich; USA), 5 µg/ml of plasmocin, gentamicin (PANECO; Russia) and 10 mL/L 100x solution of penicillin/streptomycin (PanEco; Russia) were used as culture medium. Spheroids were cultured for 28 days; the medium was changed every 4 days.

Experimental design

Inbred Balb/c Nude immunodeficient mice were selected for safety assessment. BCPs were administered to animals ($n = 12$; 6 females, 6 males) by a single subcutaneous injection in the head in a dose of five spheroids in saline (groups 1, 2). In addition, 12 mice (6 males and 6 females) were used as control animals that received subcutaneous injection of 50 µL of saline (groups 3, 4). The animals were weighted regularly, and the inoculum size was measured in the implantation area during the experiment. Then, 90 calendar days after administration 12 females and 12 males were euthanized by decapitation under inhalation anesthesia. After that specimens from the following organs and tissues were harvested: lymph nodes, thyroid,

Table 1. Primers used in the study

Name	Sequence 5'→3'	Product size
mActb-F	GAT GCA CAG TAG GTC TAA GTG GAG	121
mActb-R	CAC TCA GGG CAG GTG AAA CT	
CO1-F	CAA CCT CAA CAC CAC CTT C	269
CO1-R	CTC GTG TGT CTA CGT CTA TTC	

aorta, heart, lungs, thymus, esophagus, stomach, pancreas, small intestine, large intestine, liver, spleen, kidney, bladder, adrenal glands, brain, testes, ovary, administration site, blood, tumor.

The euthanized animal was treated with 96% ethanol. All subsequent phases of organ harvesting were accomplished under a laminar flow hood in aseptic environment.

Histological analysis

Biomaterial was fixed in the Histosafe 10% formaldehyde solution (BioVitrum; Russia) for 24 h, then washed with running water for 20 min to remove excess fixing agent and dehydrated five times with the Blic modified isopropyl alcohol (BlicMedicalProduction; Russia). Then the specimens were embedded in paraffin. The 4–5 µm histological sections were obtained using the Microm HM325 microtome (Microm; Germany). Paraffin removal was performed in accordance with the following scheme: xylene № 1 — 2 min, xylene № 2 — 2 min, 96% ethanol № 1 — 2 min, 96% ethanol № 2 — 2 min, 70% ethanol — 2 min, distilled water — 2 min. Histological sections were stained with hematoxylin and eosin (Mayer's haematoxylin, eosin 1% aqueous solution (BioVitrum; Russia)). The resulting slices were assessed using the Levenhuk 625 microscope (Levenhuk; Russia).

Genomic DNA isolation

The M-SORB-OOM kit (Sintol; Russia) was used in accordance with the manufacturer's instructions to extract genomic DNA from the organs of mice and human capillary blood to be used as positive control for human DNA. The 10–20 mg fragments of organs or 10–20 µL of capillary blood were used for extraction. Samples with no organ or tissue specimens were used as negative controls. Genomic DNA was eluted in 400 µL of elution buffer. The finite volume of the solution with isolated genomic DNA was 400 µL.

Polymerase chain reaction (PCR)

PCR was performed in the CFX96 Touch system for nucleic acid amplification (Bio-Rad; USA) using the ready-made 5X Screen Mix for PCR (Evrogen; Russia) in accordance with the manufacturer's instructions. We used primers specific for the cytochrome C oxidase subunit I (CO1) genes to detect human DNA and β-actin specific for mice (mActb) to detect murine DNA when performing the reaction (Table 1).

Amplification was performed in accordance with the following protocol:

- 1) 95 °C — 5 min;
- 2) 95 °C — 15 s;
- 3) 58 °C — 15 s;
- 4) 72 °C — 30 s.

Steps 2, 3 and 4 were repeated in 40 cycles.

Agarose gel electrophoresis

DNA electrophoresis was conducted in 1% agarose gel in Tris-Acetate-EDTA (TAE) buffer in the horizontal electrophoresis

chamber (Biorad; USA). Visual detection of amplification products involved the use of 0.5 µg/mL ethidium bromide. Voltage was set as 120 V, and the run time was 20 min. The amplification products were detected with the UV transilluminator (Vilber; Germany).

Statistical analysis

The results of weight estimation in the animal subjects were processed using the Microsoft Excel (Microsoft; USA) and SPSS Statistics 17.0 (IBM; USA) software packages. The Shapiro-Wilk test was used to test the trait distribution for normality. Mann-Whitney U-test was used for comparison. Bonferroni correction for multiple comparisons was applied. The differences between groups were considered significant at $p < 0.05$. Graphs were plotted with the GraphPad Prism software (Dotmatics; USA).

Handling the remaining BCPs

BCPs not used in the experiment were autoclaved and disposed as class B waste.

RESULTS

Morphometric analysis

Regular weighting for 90 days revealed no significant differences in body weight between the groups receiving BCPs and control groups (Fig. 1).

There were no significant differences in the animals' general health between the experimental and control groups. The animals remained active and showed normal feeding behavior.

Histological analysis

After histological staining of specimens from the BCP implantation area we observed stable cartilage tissue with the large number of chondrocytes and the emerging lacunae (Fig. 2). Cell migration from the implantation area was minimal.

Detection of human DNA in murine tissues and organs

The analysis of whole blood samples, murine organ and tissue specimens revealed human DNA in the chondrosphere injection area only (Table 2). No traces of the tested BCP were detected in other tissues and organs of male and female mice (LOQ < 0.001 ng of DNA). Thus, the BCP biodistribution pattern was optimal for the recommended administration route.

DISCUSSION

Obtaining 3D spheroid BCPs based on autologous human chondrocytes using the organoid technique is considered to be a rather promising direction of the development of products for cell therapy of large focal hyaline cartilage defects [28]. Despite the fact that the composition of the product we are

developing now is similar to that of the product by Generium, it is obtained using a modified technique, which requires safety testing. According to the current standards, the study of BCP pharmacokinetics includes assessment of biodistribution characterizing migration potential of the cells comprised in the construct [27]. Previously, the Spherotm product researchers assessed biodistribution of their invention implanted in immunodeficient animals as part of registration activities after consulting with the regulator [8]. The analysis by PCR showed that there were no human DNA in the tissues and organs distant from the subcutaneous implantation site. Thus, it seems reasonable to assess biodistribution of BCPs designed for implantation in humans using the discussed approach within the framework of safety testing.

Our study was aimed to assess biodistribution of the spheroid BCP designed for treatment of human articular cartilage lesions in immunodeficient mice. As far as we know, this is the first large-scale preclinical trial of BCP based on autologous chondrocytes in the Russian Federation.

Balb/c Nude mice were used to assess biodistribution. These immunodeficient mice are widely used in the trials of xenografts, including that based on human chondrocytes [29–30]. We used subcutaneous implantation of spheroids, since this procedure is less invasive, expandable and easier to implement — for example, compared to implantation in the small rodent's joint. A single BCP dose was calculated based on the estimated therapeutic dose for humans in accordance to the cartilage tissue defect size: 10–70 spheroids per 1 cm² of damaged tissue [8]. In mice, the dose was five spheroids per animal.

To assess stable cartilage tissue formation in the BCP administration site, the injection sites were examined using histological analysis. We observed cartilage tissue development 90 days after implantation, which was indicative of successful integration of spheroids into murine tissues. Morphometry revealed no significant changes in body weight in the experimental groups, which suggested no systemic morbid effect. Furthermore, there was no abnormal tissue growth associated with carcinogenesis (month 3 of follow-up) or tumorigenesis.




Fig. 1. Changes in the experimental animals' body weight by groups before and after the experiment. 1, 2 — groups of males and females, which underwent BCP implantation, $n = 12$; 3, 4 — groups of males and females, which received subcutaneous injection of saline, $n = 12$. * — significant intragroup differences, $p < 0.05$

To assess biodistribution, biopsy specimens of murine organs and tissues were qualitatively tested for expression of the human-specific sequence of the gene encoding cytochrome C oxidase subunit 1 (COI) 90 days after implantation. Our findings showed that a single subcutaneous administration of BCP to experimental mice resulted in the fact that human DNA was detected exclusively in the administration site, not in the other assessed tissues and organs. Thus, human DNA is related exclusively to the cells comprised in the spheroids implanted. However, in the future we plan to assess BCP biodistribution and carcinogenicity in mice throughout a longer period after implantation in order to evaluate potential delayed effects.




Fig. 2. Chondropheres in murine tissues 90 days after implantation. Hematoxylin and eosin stain. 10x magnification. Scale bar — 100 μm

Table 2. Human DNA detection

Organ/Tissue	Group number (n = 24)			
	1	2	3	4
Lymph nodes	-----	-----	-----	-----
Thyroid	-----	-----	-----	-----
Aorta	-----	-----	-----	-----
Heart	-----	-----	-----	-----
Lung	-----	-----	-----	-----
Thymus	-----	-----	-----	-----
Esophagus	-----	-----	-----	-----
Stomach	-----	-----	-----	-----
Pancreas	-----	-----	-----	-----
Small intestine	-----	-----	-----	-----
Liver	-----	-----	-----	-----
Spleen	-----	-----	-----	-----
Kidney	-----	-----	-----	-----
Bladder	-----	-----	-----	-----
Adrenal glands	-----	-----	-----	-----
Brain	-----	-----	-----	-----
Testes	-----	-----	-----	-----
Ovary	-----	-----	-----	-----
Implantation site	++++++	++++++	-----	-----
Blood	-----	-----	-----	-----
Tumor	-----	-----	-----	-----

Note: Positive (indicative of the presence of human DNA) qualitative data were obtained for the samples designated as "+"; 1, 2 — groups that received BCP; 3, 4 — groups that received saline.

The results obtained in this phase suggest no cell migration processes, which indicates that the product developed is safe in terms of biodistribution.

CONCLUSIONS

In this study we assessed biodistribution of BCPs in the form of chondrospheres based on human chondrocytes by

subcutaneous implantation to Balb/c Nude mice. During the study we observed the development of stable mature cartilage tissue showing no signs of abnormal proliferation or cell migration outside the implantation site. Such findings allow us to conclude that the BCP developed is characterized by normal biodistribution within the administration site and successful integration into the surrounding tissues. Thus, this cell engineering product, Chondrosphere, can be recommended for further testing.

References

1. Ramezankhani R, Torabi S, Minaei N, Madani H, Rezaeiani S, Hassani SN, et al. Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies. *Front Cell Dev Biol.* 2020; 8: 547653. DOI:10.3389/fcell.2020.547653.
2. Kim J, Park J, Song SY, Kim E. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries. *Regen Ther.* 2022; 20: 126–37. DOI: 10.1016/j.reth.2022.04.004.
3. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with ACL. *N Engl J Med.* 1994; 331 (14): 889–95.
4. Fontana A, Bistolfi A, Crova M, Rosso F, Massazza G. Arthroscopic treatment of hip chondral defects: Autologous chondrocyte transplantation versus simple debridement —A pilot study. *Arthrosc — J Arthrosc Relat Surg.* 2012; 28 (3): 322–9. DOI: 10.1016/j.arthro.2011.08.304.
5. Saris D, Price A, Widuchowski W, Bertrand-Marchand M, Caron J, Drogset JO, et al. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: Two-year follow-up of a prospective randomized trial. *Am J Sports Med.* 2014; 42 (6): 1384–94. DOI: 10.1177/0363546514528093.
6. Yoon KH, Yoo JD, Choi CH, Lee J, Lee JY, Kim SG, et al. Costal Chondrocyte-Derived Pellet-Type Autologous Chondrocyte Implantation versus Microfracture for Repair of Articular Cartilage Defects: A Prospective Randomized Trial. *Cartilage.* 2021; 13 (1): 1092S–1104S. DOI: 10.1177/1947603520921448.
7. Hoburg A, Niemeyer P, Laute V, Zinser W, Becher C, Kolombe T, et al. Matrix-Associated Autologous Chondrocyte Implantation with Spheroid Technology Is Superior to Arthroscopic Microfracture at 36 Months Regarding Activities of Daily Living and Sporting Activities after Treatment. *Cartilage.* 2021; 13 (1): 437S–448S. DOI: 10.1177/1947603519897290.
8. Zscharnack M, Krause C, Aust G, Thümmeler C, Peinemann F, Keller T, et al. Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP). *J Transl Med.* 2015; 13 (1): 1–17. DOI: 10.1186/s12967-015-0517-x.
9. Fickert S, Gerwien P, Helmert B, Schattenberg T, Weckbach S, Kaszkin-Bettag M, et al. One-Year Clinical and Radiological Results of a Prospective, Investigator-Initiated Trial Examining a Novel, Purely Autologous 3-Dimensional Autologous Chondrocyte Transplantation Product in the Knee. *Cartilage.* 2012; 3 (1): 27–42. DOI: 10.1177/1947603511417616.

10. Spherox. European Medicines Agency. [cited 2023 Oct 26]. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/spherox>.
11. Study Details. The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy. ClinicalTrials.gov. [cited 2023 Oct 26]. Available from: <https://clinicaltrials.gov/study/NCT02539069?cond=Osteoarthritis&intr=Chondrocytes&page=2&rank=13>.
12. Choi NY, Kim BW, Yeo WJ, Kim HB, Suh DS, Kim JS, et al. Gel-type autologous chondrocyte (Chondron) implantation for treatment of articular cartilage defects of the knee. *BMC Musculoskelet Disord*. 2010; 11. DOI: 10.1186/1471-2474-11-103.
13. Pathak S, Chaudhary D, Reddy KR, Acharya KKV, Desai SM. Efficacy and safety of CARTIGROW® in patients with articular cartilage defects of the knee joint: a four year prospective study. *Int Orthop*. 2022; 46 (6): 1313–21. DOI: 10.1007/s00264-022-05369-2.
14. Crowe R, Willers C, Cheng T, Wang L, Zheng MH. Evaluation of Intraoperative Retention of Autologous Chondrocytes on Type I/III Collagen Scaffold (Ortho-ACITM) for Cartilage Repair. *J Foot Ankle Res*. 2015; 8 (S2): 2015. DOI: 10.1186/1757-1146-8-s2-p10.
15. Riedl M, Vadalà G, Papalia R, Denaro V. Three-dimensional, Scaffold-Free, Autologous Chondrocyte Transplantation: A Systematic Review. *Orthop J Sport Med*. 2020; 8 (9): 1–7. DOI: 10.1177/2325967120951152.
16. Shah SS, Mithoefer K. Scientific Developments and Clinical Applications Utilizing Chondrons and Chondrocytes with Matrix for Cartilage Repair. *Cartilage*. 2021; 13 (1): 119S–120S. DOI: 10.1177/1947603520968884.
17. Schubert T, Anders S, Neumann E. Long-term effects of chondrospheres on cartilage lesions in an autologous chondrocyte implantation model as investigated in the SCID mouse model. *Int J Mol Med*. 2009; 23 (4): 455–60. DOI: 10.3892/ijmm.
18. Körsmeier K, Claßen T, Kamminga M, Rekowski J, Jäger M, Landgraeber S. Arthroscopic three-dimensional autologous chondrocyte transplantation using spheroids for the treatment of full-thickness cartilage defects of the hip joint. *Knee Surgery, Sport Traumatol Arthrosc*. 2016; 24 (6): 2032–7. DOI: 10.1007/s00167-014-3293-x.
19. Niemeyer P, Laute V, Zinser W, John T, Becher C, Diehl P, et al. Safety and efficacy of matrix-associated autologous chondrocyte implantation with spheroid technology is independent of spheroid dose after 4 years. *Knee Surgery, Sport Traumatol Arthrosc*. 2020; 28 (4): 1130–43. DOI: 10.1007/s00167-019-05786-8.
20. Bartz C, Meixner M, Giesemann P, Roël G, Bulwin GC, Smink JJ. An ex vivo human cartilage repair model to evaluate the potency of a cartilage cell transplant. *J Transl Med*. 2016; 14 (1): 1–15. DOI: 10.1186/s12967-016-1065-8.
21. Prikaz Ministerstva zdravookhraneniya Rossiyskoy Federatsii ot 30 oktyabrya 2018 g. 512N «Ob utverzhdenii pravil nadlezhashchey praktiki po rabote s biomeditsinskimi kletochnymi produktami». P. 1–71. Russian.
22. Satué M, Schüller C, Ginner N, Erben RG. Intra-articularly injected mesenchymal stem cells promote cartilage regeneration, but do not permanently engraft in distant organs. *Sci Rep*. 2019; 9 (1): 1–10. DOI: 10.1038/s41598-019-46554-5.
23. Marquina M, Collado JA, Pérez-Cruz M, Fernández-Pernas P, Fafián-Labora J, Blanco FJ, et al. Biodistribution and immunogenicity of allogeneic mesenchymal stem cells in a rat model of intraarticular chondrocyte xenotransplantation. *Front Immunol*. 2017; 8 (NOV): 1–14. DOI: 10.3389/fimmu.2017.01465.
24. Erben RG, Silva-Lima B, Reischl I, Steinhoff G, Tiedemann G, Dalemans W, et al. White paper on how to go forward with cell-based advanced therapies in Europe. *Tissue Eng — Part A*. 2014; 20 (19–20): 2549–54. DOI: 10.1089/ten.tea.2013.0589.
25. Federal'nyy zakon ot 23 iyunya 2016 g. №180-FZ «O biomeditsinskikh kletochnykh produktakh». Russian.
26. GOST 33044-2014. Printsipy nadlezhashchey laboratornoy praktiki. Mezhsudarstvennyy standart. Data vvedeniya: 1 avgusta 2015 g. Russian.
27. Mironov AN, Bunyatyan ND. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv. M.: Grif i K, 2012; 944 p. Russian.
28. Ereemov AV, Belikova LD, Ruchko EA, Volovikov EA, Zubkova OA, Emelin AM, et al. Brain Organoid Generation from Induced Pluripotent Stem Cells in Home-Made Mini Bioreactors. *J Vis Exp*. 2021; 2021 (178). DOI: 10.3791/62987.
29. Chen Y, Ma M, Teng Y, Cao H, Yang Y, Wang Y, et al. Efficient manufacturing of tissue engineered cartilage: In vitro by a multiplexed 3D cultured method. *J Mater Chem B*. 2020; 8 (10): 2082–95. DOI: 10.1039/c9tb01484e.
30. Apelgren P, Amoroso M, Lindahl A, Brantsing C, Rotter N, Gatenholm P, et al. Chondrocytes and stem cells in 3D-bioprinted structures create human cartilage in vivo. *PLoS One*. 2017; 12 (12): 1–16. DOI: 10.1371/journal.pone.0189428.

Литература

1. Ramezankhani R, Torabi S, Minaei N, Madani H, Rezaeiani S, Hassani SN, et al. Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies. *Front Cell Dev Biol*. 2020; 8: 547653. DOI:10.3389/fcell.2020.547653.
2. Kim J, Park J, Song SY, Kim E. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries. *Regen Ther*. 2022; 20: 126–37. DOI: 10.1016/j.reth.2022.04.004.
3. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with ACL. *N Engl J Med*. 1994; 331 (14): 889–95.
4. Fontana A, Bistolfi A, Crova M, Rosso F, Massazza G. Arthroscopic treatment of hip chondral defects: Autologous chondrocyte transplantation versus simple debridement — A pilot study. *Arthrosc — J Arthrosc Relat Surg*. 2012; 28 (3): 322–9. DOI: 10.1016/j.arthro.2011.08.304.
5. Saris D, Price A, Widuchowski W, Bertrand-Marchand M, Caron J, Drogset JO, et al. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: Two-year follow-up of a prospective randomized trial. *Am J Sports Med*. 2014; 42 (6): 1384–94. DOI: 10.1177/0363546514528093.
6. Yoon KH, Yoo JD, Choi CH, Lee J, Lee JY, Kim SG, et al. Costal Chondrocyte-Derived Pellet-Type Autologous Chondrocyte Implantation versus Microfracture for Repair of Articular Cartilage Defects: A Prospective Randomized Trial. *Cartilage*. 2021; 13 (1): 1092S–1104S. DOI: 10.1177/1947603520921448.
7. Hoburg A, Niemeyer P, Laute V, Zinser W, Becher C, Kolombe T, et al. Matrix-Associated Autologous Chondrocyte Implantation with Spheroid Technology Is Superior to Arthroscopic Microfracture at 36 Months Regarding Activities of Daily Living and Sporting Activities after Treatment. *Cartilage*. 2021; 13 (1): 437S–448S. DOI: 10.1177/1947603519897290.
8. Zscharnack M, Krause C, Aust G, Thümmel C, Peinemann F, Keller T, et al. Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP). *J Transl Med*. 2015; 13 (1): 1–17. DOI: 10.1186/s12967-015-0517-x.
9. Fickert S, Gerwien P, Helmert B, Schattenberg T, Weckbach S, Kaszkin-Bettag M, et al. One-Year Clinical and Radiological Results of a Prospective, Investigator-Initiated Trial Examining a Novel, Purely Autologous 3-Dimensional Autologous Chondrocyte Transplantation Product in the Knee. *Cartilage*. 2012; 3 (1): 27–42. DOI: 10.1177/1947603511417616.
10. Spherox. European Medicines Agency. [cited 2023 Oct 26]. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/spherox>.
11. Study Details. The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy. ClinicalTrials.gov. [cited 2023 Oct 26]. Available

- from: <https://clinicaltrials.gov/study/NCT02539069?cond=Osteoarthritis&intr=Chondrocytes&page=2&rank=13>.
12. Choi NY, Kim BW, Yeo WJ, Kim HB, Suh DS, Kim JS, et al. Gel-type autologous chondrocyte (Chondron) implantation for treatment of articular cartilage defects of the knee. *BMC Musculoskelet Disord*. 2010; 11. DOI: 10.1186/1471-2474-11-103.
 13. Pathak S, Chaudhary D, Reddy KR, Acharya KKV, Desai SM. Efficacy and safety of CARTIGROW® in patients with articular cartilage defects of the knee joint: a four year prospective study. *Int Orthop*. 2022; 46 (6): 1313–21. DOI: 10.1007/s00264-022-05369-2.
 14. Crowe R, Willers C, Cheng T, Wang L, Zheng MH. Evaluation of Intraoperative Retention of Autologous Chondrocytes on Type I/III Collagen Scaffold (Ortho-ACITM) for Cartilage Repair. *J Foot Ankle Res*. 2015; 8 (S2): 2015. DOI: 10.1186/1757-1146-8-s2-p10.
 15. Riedl M, Vadalà G, Papalia R, Denaro V. Three-dimensional, Scaffold-Free, Autologous Chondrocyte Transplantation: A Systematic Review. *Orthop J Sport Med*. 2020; 8 (9): 1–7. DOI: 10.1177/2325967120951152.
 16. Shah SS, Mithoefer K. Scientific Developments and Clinical Applications Utilizing Chondrons and Chondrocytes with Matrix for Cartilage Repair. *Cartilage*. 2021; 13 (1): 119S–120S. DOI: 10.1177/1947603520968884.
 17. Schubert T, Anders S, Neumann E. Long-term effects of chondrospheres on cartilage lesions in an autologous chondrocyte implantation model as investigated in the SCID mouse model. *Int J Mol Med*. 2009; 23 (4): 455–60. DOI: 10.3892/ijmm.
 18. Körsmeier K, Claßen T, Kamminga M, Rekowski J, Jäger M, Landgraeber S. Arthroscopic three-dimensional autologous chondrocyte transplantation using spheroids for the treatment of full-thickness cartilage defects of the hip joint. *Knee Surgery, Sport Traumatol Arthrosc*. 2016; 24 (6): 2032–7. DOI: 10.1007/s00167-014-3293-x.
 19. Niemeyer P, Laute V, Zinser W, John T, Becher C, Diehl P, et al. Safety and efficacy of matrix-associated autologous chondrocyte implantation with spheroid technology is independent of spheroid dose after 4 years. *Knee Surgery, Sport Traumatol Arthrosc*. 2020; 28 (4): 1130–43. DOI: 10.1007/s00167-019-05786-8.
 20. Bartz C, Meixner M, Giesemann P, Roël G, Bulwin GC, Smink JJ. An ex vivo human cartilage repair model to evaluate the potency of a cartilage cell transplant. *J Transl Med*. 2016; 14 (1): 1–15. DOI: 10.1186/s12967-016-1065-8.
 21. Приказ Министерства здравоохранения Российской Федерации от 30 октября 2018 г. 512Н «Об утверждении правил надлежащей практики по работе с биомедицинскими клеточными продуктами». С. 1–71.
 22. Satué M, Schüler C, Ginner N, Erben RG. Intra-articularly injected mesenchymal stem cells promote cartilage regeneration, but do not permanently engraft in distant organs. *Sci Rep*. 2019; 9 (1): 1–10. DOI: 10.1038/s41598-019-46554-5.
 23. Marquina M, Collado JA, Pérez-Cruz M, Fernández-Pernas P, Fafián-Labora J, Blanco FJ, et al. Biodistribution and immunogenicity of allogeneic mesenchymal stem cells in a rat model of intraarticular chondrocyte xenotransplantation. *Front Immunol*. 2017; 8 (NOV): 1–14. DOI: 10.3389/fimmu.2017.01465.
 24. Erben RG, Silva-Lima B, Reischl I, Steinhoff G, Tiedemann G, Dalemans W, et al. White paper on how to go forward with cell-based advanced therapies in Europe. *Tissue Eng — Part A*. 2014; 20 (19–20): 2549–54. DOI: 10.1089/ten.tea.2013.0589.
 25. Федеральный закон от 23 июня 2016 г. №180-ФЗ «О биомедицинских клеточных продуктах».
 26. ГОСТ 33044-2014. Принципы надлежащей лабораторной практики. Межгосударственный стандарт. Дата введения: 1 августа 2015 г.
 27. Миронов А. Н., Бунятян Н. Д. Руководство по проведению доклинических исследований лекарственных средств. М.: Гриф и К, 2012; 944 с.
 28. Ereemeev AV, Belikova LD, Ruchko EA, Volovikov EA, Zubkova OA, Emelin AM, et al. Brain Organoid Generation from Induced Pluripotent Stem Cells in Home-Made Mini Bioreactors. *J Vis Exp*. 2021; 2021 (178). DOI: 10.3791/62987.
 29. Chen Y, Ma M, Teng Y, Cao H, Yang Y, Wang Y, et al. Efficient manufacturing of tissue engineered cartilage: In vitro by a multiplexed 3D cultured method. *J Mater Chem B*. 2020; 8 (10): 2082–95. DOI: 10.1039/c9tb01484e.
 30. Apelgren P, Amoroso M, Lindahl A, Brantsing C, Rotter N, Gatenholm P, et al. Chondrocytes and stem cells in 3D-bioprinted structures create human cartilage in vivo. *PLoS One*. 2017; 12 (12): 1–16. DOI: 10.1371/journal.pone.0189428.